Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

149 49,465

Net cash provided by operating

activities 282,777 274,321

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and

equipment (55,689) (70,887)

Acquisition of intangible assets (25,575) (99,152)

Investment in third party (6,242) -

Proceeds from sale of investment

in third party - 12,291

Sales and maturities of

available-for-sale investments 7,596 28,212

Purchases of available-for-sale

investments - (71,398)

Net cash used for investing

activities (79,910) (200,934)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of

common stock options 37,185 74,375

Windfall tax benefits from

stock-based compensation 4,592 9,934

Acquisition of treasury stock (24) (128)

Payments on and retirements of

long-term debt (216,093) (2,902)

Net cash (used for) provided

by financing activities (174,340) 81,279

EFFECT OF EXCHANGE RATE CHANGES ON

CASH AND CASH EQUIVALENTS (601) 10,804

NET INCREASE IN CASH AND CASH

EQUIVALENTS 27,926 165,470

CASH AND CASH EQUIVALENTS, BEGINNING

OF PERIOD 818,669 496,512

CASH AND CASH EQUIVALENTS, END OF

PERIOD
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 3.75% Convertible Senior Notes due May 1, 2015 ... $1,000 principal amount or approximately $5.72 per share, effective March 3, ... is adjusted in connection with the regular quarterly dividend of ... who own shares of PDL on March 5, 2015, the record ...
(Date:3/4/2015)... The UPMC Center for Health Security today announced the ... in Biosecurity Initiative (ELBI). As part of our commitment ... UPMC has selected 28 US and international emerging leaders ... biological science, medicine, policy, the military, think tanks and ... and support of the Defense Threat Reduction Agency in ...
(Date:3/4/2015)... USDM Life Sciences , a leading ... hired David Blewitt as Vice President of ... and Solutions at USDM Life Sciences , which help ... compliance with government regulations worldwide. , For more ... sciences regulatory and IS compliance professional with extensive hands-on ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... 2011 Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ... systems, announced today that its work entitled "Evaluation of ... in Healthy Volunteers" will be presented at the Eleventh ... held in San Francisco, California. "The selection ...
... N.J., Oct. 25, 2011 Quest Diagnostics Incorporated (NYSE: ... has begun the process of identifying a successor to Surya ... Board of Directors has formed a search committee, engaged a ... internal candidates. Dr. Mohapatra has agreed to ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... update on operations and disclosed the outcome of a ... by management and AMT,s Board of Directors that enables ... therapy development. The CHMP,s recent opinion, while not approving ...
Cached Biology Technology:Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA) 2Quest Diagnostics Initiates CEO Succession Process 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 3Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 4
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... light," winners are able to stop, and take off ... reveals that a similar race goes on in our ... "The research provides new insights into how the brain ... with attention deficit and hyperactivity disorder," study co-author Jeffrey ...
... owner than a lost cat, according to two new studies. , In ... lost dogs were found, compared to just 53 percent of lost cats. ... by a call or visit to an animal shelter. More than one ... or identification tag at the time of its disappearance. , "The ...
... M.D., Professor of Medicine and Pharmacology at the University ... studied about 265 twin pairs over the past few ... , "By studying many traits and genes, we have ... , Studying genetic variations in twins provides scientists with ...
Cached Biology News:Racing neurons control whether we stop or go 2Racing neurons control whether we stop or go 3Lost dogs found more often than lost cats, study suggests 2Lost dogs found more often than lost cats, study suggests 3Twin studies reveal genetic components leading to cardiac and kidney disease 2Twin studies reveal genetic components leading to cardiac and kidney disease 3
Topoisomerase I...
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Biology Products: